How does erythromycin prevent bacterial growth

The authors gratefully acknowledge T. Willems for teaching us in vitro culture techniques and for his assistance in scanning electron microscopy and measurement of CBF. We thank J. Van den Oord for immunohistochemical staining and R. De Vos for transmission electron microscopy. We also thank A. Hoefnagels-Schuermans for her valuable suggestions and information.

This work was supported in part by the Glaxo Wellcome chair in medical microbiology J. Labro, M. Anti-inflammatory activity of macrolides: a new therapeutic potential? Journal of Antimicrobial Chemotherapy 41 , Suppl. B , 37 — Goswami, S. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. American Review of Respiratory Disease , 72 —8.

Takeyama, K. Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in vitro. Journal of Pharmacy and Pharmacology 45 , —8.

Suzuki, H. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope , —6. Ishida, L. Erythromycin inhibits adhesion of Pseudomonas aeruginosa and Branhamella catarrhalis to human nasal epithelial cells. American Journal of Rhinology 9 , 53 —5. Lagrou, K. Macrolide resistance in Belgian Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 45 , — Jorissen, M.

The preservation and regeneration of cilia on human nasal epithelial cells cultured in vitro. Archives of Otorhinolaryngology , — Yamaya, M. Differentiated structure and function of cultures from human tracheal epithelium. American Journal of Physiology , L — Hoefnagels-Schuermans, A. Staphylococcus aureus adherence to nasal epithelial cells in a physiological in vitro model.

Normal ciliary beat frequency after ciliogenesis in nasal epithelial cells cultured sequentially as monolayer and in suspension. Acta Oto-Laryngologica , 66 — Weiser, J. Phase variation in pneumococcal opacity: relationship between colonial morphology and nasopharyngeal colonization.

Infection and Immunity 62 , —9. Wuyts, A. European Journal of Biochemistry , —9. Journal of Immunology , — Paton, J. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae.

Infection and Immunity 40 , — Adamou, J. Infection and Immunity 66 , —2. Andersson, B. Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells.

Journal of Experimental Medicine , — Cundell, D. Relationship between colonial morphology and adherence of Streptococcus pneumoniae. Infection and Immunity 63 , — Rayner, C. Interaction of pneumolysinsufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infection and Immunity 63 , —7. Talbot, U. Uptake of Streptococcus pneumoniae by respiratory epithelial cells.

Infection and Immunity 64 , —7. Werner, U. In-vitro cell culture models of the nasal epithelium: a comparative histochemical investigation of their suitability for drug transport studies. Pharmaceutical Research 13 , — Cereijido, M. Epithelial tight junctions. American Review of Respiratory Disease , S17 — Stosiek, P. Changes in cytokeratin expression accompany squamous metaplasia of the human respiratory epithelium. Yamasaki, T. Effect of antimicrobial agents on the piliation of Pseudomonas aeruginosa and adherence to mouse tracheal epithelium.

Journal of Chemotherapy 9 , 32 —7. Rosenow, C. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Molecular Microbiology 25 , — Feldman, C. Antibiotics such as erythromycin will not work for colds, flu, or other viral infections. Taking antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.

Erythromycin comes as a capsule, tablet, delayed-release releases the medication in the intestine to prevent break-down of the medication by stomach acids capsule, delayed-release tablet, and an oral suspension liquid to take by mouth. It usually is taken with or without food every 6 hours four times a day , every 8 hours three times a day , or every 12 hours twice a day.

Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand.

Take erythromycin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. If you are taking the suspension, do not use a household spoon to measure your dose. Use the measuring spoon, dropper, or cup that came with the medication or use a spoon made especially for measuring medication. Continue to take erythromycin even if you feel well.

Do not stop taking erythromycin without talking to your doctor. Erythromycin is also used sometimes used to prevent heart infection in people having dental or other procedures. Talk to your doctor about the possible risks of using this medication for your condition. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one. Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture not in the bathroom.

It is important to keep all medication out of sight and reach of children as many containers such as weekly pill minders and those for eye drops, creams, patches, and inhalers are not child-resistant and young children can open them easily.

To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location — one that is up and away and out of their sight and reach.

Weisblum, B. Erythromycin resistance by ribosome modification. Agents Chemother. Vester, B. Macrolide resistance conferred by base substitutions in 23S rRNA. Gregory, S. Erythromycin resistance mutations in ribosomal proteins L22 and L4 perturb the higher order structure of 23S ribosomal RNA. Moore, S. Revisiting the mechanism of macrolide-antibiotic resistance mediated by ribosomal protein L Starosta, A.

Interplay between the ribosomal tunnel, nascent chain, and macrolides influences drug inhibition. Cell Chem. CAS Google Scholar. The general mode of translation inhibition by macrolide antibiotics.

Morten, K. Template-based protein structure modeling using the RaptorX web server. Abraham, M. SoftwareX 1 , 19—25 Storn, R. Differential evolution—a simple and efficient heuristic for global optimization over continuous spaces.

Journal of Global Optimization 11 , — Sergei, I. Molecular dynamics study of unbinding of the avidin-biotin complex. Essmann, U. A smooth particle mesh Ewald method. Bussi, G. Canonical sampling through velocity rescaling. Parrinello, M. Polymorphic transitions in single crystals: A new molecular dynamics method. Vuong, Q.

Kyte, J. A simple method for displaying the hydropathic character of a protein. A combined cryo-EM and molecular dynamics approach reveals the mechanism of ErmBL-mediated translation arrest.

Deng, N. Free energy profile of RNA hairpins: a molecular dynamics simulation study. Spasic, A. The Amber ff99 force field predicts relative free energy changes for RNA helix formation. Theory Comput. Piana, S. How robust are protein folding simulations with respect to force field parameterization?

Download references. We are indebted to Dr. Bo Liu for providing us the topology file of ERY. You can also search for this author in PubMed Google Scholar. Correspondence to Edward P. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Reprints and Permissions. Nguyen, H.

Erythromycin leads to differential protein expression through differences in electrostatic and dispersion interactions with nascent proteins. Sci Rep 8, Download citation. Received : 15 September Accepted : 23 March Published : 24 April Anyone you share the following link with will be able to read this content:.

Sorry, a shareable link is not currently available for this article. Provided by the Springer Nature SharedIt content-sharing initiative. Scientific Reports By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Advanced search. Skip to main content Thank you for visiting nature. Download PDF. Subjects Computational chemistry Mechanism of action Molecular dynamics Ribosomal proteins.

Abstract The antibiotic activity of erythromycin, which reversibly binds to a site within the bacterial ribosome exit tunnel, against many gram positive microorganisms indicates that it effectively inhibits the production of proteins.

Introduction Antibiotics are a type of antimicrobial that kills bacteria by inhibiting their growth and replication. Figure 1. Full size image. Table 1 Rupture force in the absence and presence of ERY in the exit tunnel.

Full size table. Table 2 Nonequilibrium work in the absence and presence of ERY in the exit tunnel. Figure 2. Figure 3. Figure 4. Table 4 Nonequilibrium work and rupture force in the presence of ERY in the exit tunnel when the non-bonded parameters of residues of nascent peptides are turned on by sequence. Figure 5. Figure 6. Figure 7. References 1. Article Google Scholar CAS Google Scholar Acknowledgements We are indebted to Dr. View author publications.

Ethics declarations Competing Interests The authors declare no competing interests. Additional information Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.